Dr. Tamar Ben-Yedidia has more than 30 years of experience in the field of immunology, with specific expertise in the development of vaccines and Immunotherapeutics. She started her career with Biotechnology General Ltd, BTG (IL), working on the development of a recombinant Hepatitis-B vaccine.

She joined the Weizmann Institute of Science in 1994, and under the auspices of Prof. Ruth Arnon in the Department of Immunology, worked on the design of a peptide-based vaccine against several pathogens and focused on influenza. She continued this work when she left the Weizmann Institute in 2004 to join Scinai (then known as BiondVax).

Dr. Ben-Yedidia was involved in two European Consortium projects related to evaluation of different approaches for vaccination in which leading academic institutions and pharma companies participated. She led the pre clinical and clinical development of an influenza vaccine candidate, including 7 clinical trials in Europe and US from Phase 1 to a pivotal phase 3 that was conducted in 7 European countries with more than 12,000 participants.  Now, focusing on the development of biological Immunotherapeutics for autoimmune diseases such as psoriasis, Dr. Ben-Yedidia is leading the proof-of-concept pre clinical and clinical studies. Dr. Ben-Yedidia is often invited to address conferences around the world and is widely published, with numerous refereed articles and invited reviews in various renowned scientific journals.